A5028534130- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Cells and Metastasis
- Lymphoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cellular Mechanics and Interactions
- Mathematical Biology Tumor Growth
- Cancer, Hypoxia, and Metabolism
- Muscle Physiology and Disorders
- Liver Disease Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Cerebrospinal fluid and hydrocephalus
- Growth Hormone and Insulin-like Growth Factors
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Endoplasmic Reticulum Stress and Disease
- Ferroptosis and cancer prognosis
- Viral-associated cancers and disorders
- GABA and Rice Research
- Genetic and Kidney Cyst Diseases
- DNA Repair Mechanisms
- Microfluidic and Bio-sensing Technologies
- Lung Cancer Diagnosis and Treatment
- Microtubule and mitosis dynamics
The University of Texas MD Anderson Cancer Center
2017-2023
Nanyang Technological University
2014-2020
Abstract Purpose: Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical hepatocellular carcinoma (HCC) given the challenge of obtaining liver tissue biopsies. Experimental Design: We analyzed blood samples from 206 with HCC using comprehensive genomic testing (Guardant Health) circulating tumor DNA (ctDNA). Results: A total 153/206 (74.3%) were men; median age, 62 years (range, 18–91 years). 181/206 had ≥1...
Membrane integrity at the endoplasmic reticulum (ER) is tightly regulated, and its disturbance implicated in metabolic diseases. Using an engineered sensor that activates unfolded protein response (UPR) exclusively when normal ER membrane lipid composition compromised, we identified pathways beyond metabolism are necessary to maintain yeast C. elegans. To systematically validate mutants disrupt homeostasis, a bilayer stress (LBS) UPR transducer Ire1, located interface of amphipathic...
Background : Ten to fourteen percent of Ewing sarcoma (ES) study participants treated nationwide with IGF-1 receptor (IGF-1R)-targeted antibodies achieved tumor regression. Despite this success, low response rates and short durations (approximately 7-weeks) have slowed the development therapy. Methods: We performed a meta-analysis five phase-1b/2 ES-oriented trials that evaluated anticancer activity IGF-1R +/− mTOR inhibitors (mTORi). Our provided head-to-head comparison clinical benefits...
Introduction: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancers. It an aggressive neoplasm with dismal outcome because patients present advanced-stage disease, which precludes curative surgical options. Therefore, these require systemic therapies that typically induce small improvements in overall survival. Hence, it crucial to identify new and promising therapeutic targets for HCC improve current outcome. The a key organ signaling cascade triggered by growth...
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at advanced stage, which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. Therefore, the majority of HCC require systemic therapy. Nonetheless, currently approved therapies have limited effects, particularly in and resistant disease. Hence, there a critical need to identify new molecular targets effective improve outcome. The...
Background and Aims Therapeutic, clinical trial entry stratification decisions for hepatocellular carcinoma (HCC) are made based on prognostic assessments, using staging systems small numbers of empirically selected variables that insufficiently account differences in biological characteristics individual patients’ disease. Approach Results We propose an approach constructing risk scores from circulating biomarkers produce a global characterization patient’s Plasma samples were collected...
Abstract Background Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK + ) T cell is an aggressive neoplasm. NPM-ALK, oncogenic tyrosine kinase, plays a critical role in this lymphoma. Recently, selective ALK inhibitors have emerged as first-line therapy for Unfortunately, were hindered by emergence of resistance and relapse. We previously demonstrated that type I insulin-like growth factor receptor (IGF-IR) commonly expressed activated In addition, IGF-IR NPM-ALK are physically...
<b><i>Background:</i></b> Liver reserve affects survival in hepatocellular carcinoma (HCC). Model for End-Stage Disease (MELD) score is used to predict overall (OS) and prioritize HCC patients on the transplantation waiting list, but more accurate models are needed. We hypothesized that integrating insulin-like growth factor 1 (IGF-1) levels into MELD (MELD-IGF-1) improves OS prediction as compared MELD. <b><i>Methods:</i></b> measured plasma...
Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+ ) T-cell is an aggressive neoplasm that more commonly seen in children and young adults. The pathogenesis of NPM-ALK+ not completely understood. Wild-type ALK a receptor tyrosine kinase physiologically expressed neural tissues during early stages human development, which suggests may interact with neurotrophic factors. aberrant expression NPM-ALK results from translocation between the gene on chromosome 2p23 NPM 5q35. nerve growth...
Mutation in the Wiskott-Aldrich syndrome Protein (WASP) causes (WAS), X-linked thrombocytopenia (XLT) and congenital neutropenia (XLN). The majority of missense mutations causing WAS XLT are found WH1 (WASP Homology) domain WASP, known to mediate interaction with WIP Interacting Protein) CIB1 (Calcium Integrin Binding).We analyzed two WASP mutants (L46P A47D) for their effects on T cell chemotaxis. Both mutants, WASPRL46P WASPRA47D (S1-WASP shRNA resistant) expressed well JurkatWASP-KD cells...
Sorafenib was the first systemic therapy approved for treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival and outcomes guide HCC therapy. Type 1 insulin-like growth factor (IGF-1)/CTP composite score has emerged as a potential hepatic reserve assessment tool. Our study investigated association IGF/CTP overall (OS) progression-free (PFS) treated sorafenib.In this prospective study, were...
<p>Supplemental table 1</p>
<p>Supplementary Figure 1</p>
<p>Supplemental table 2</p>
<p>Supplemental table 1</p>